1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: AI-Powered Drug Formulation Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. AI-Powered Drug Formulation Market, by Component
8.1.1. Software Platforms
8.1.1.1. Market Revenue and Forecast
8.1.2. Services
8.1.2.1. Market Revenue and Forecast
8.1.3. Hardware & Infrastructure
8.1.3.1. Market Revenue and Forecast
9.1. AI-Powered Drug Formulation Market, by Technology
9.1.1. Machine Learning & Deep Learning
9.1.1.1. Market Revenue and Forecast
9.1.2. Natural Language Processing (NLP) for literature mining
9.1.2.1. Market Revenue and Forecast
9.1.3. Predictive Modeling & Simulation
9.1.3.1. Market Revenue and Forecast
9.1.4. Generative AI & Neural Networks (novel formulation design)
9.1.4.1. Market Revenue and Forecast
9.1.5. Reinforcement Learning (process optimization)
9.1.5.1. Market Revenue and Forecast
9.1.6. Hybrid AI (AI + mechanistic models)
9.1.6.1. Market Revenue and Forecast
10.1. AI-Powered Drug Formulation Market, by Application / Use Case
10.1.1. Excipient Compatibility Prediction
10.1.1.1. Market Revenue and Forecast
10.1.2. Formulation Design & Optimization (IR, MR, ODT, biologics formulations)
10.1.2.1. Market Revenue and Forecast
10.1.3. Stability & Shelf-life Prediction
10.1.3.1. Market Revenue and Forecast
10.1.4. Bioavailability & Pharmacokinetic (PK) Simulation
10.1.4.1. Market Revenue and Forecast
10.1.5. High-Throughput Screening (HTS) Optimization
10.1.5.1. Market Revenue and Forecast
10.1.6. Personalized & Precision Medicine Formulations
10.1.6.1. Market Revenue and Forecast
10.1.7. Advanced Therapy Formulations (cell/gene therapy delivery)
10.1.7.1. Market Revenue and Forecast
11.1. AI-Powered Drug Formulation Market, by Drug Type
11.1.1. Small Molecules
11.1.1.1. Market Revenue and Forecast
11.1.2. Biologics (proteins, peptides, mAbs)
11.1.2.1. Market Revenue and Forecast
11.1.3. Nucleic Acid-Based Drugs (siRNA, mRNA, DNA)
11.1.3.1. Market Revenue and Forecast
11.1.4. Cell & Gene Therapy Payloads
11.1.4.1. Market Revenue and Forecast
11.1.5. Vaccines (traditional and mRNA-based)
11.1.5.1. Market Revenue and Forecast
12.1. AI-Powered Drug Formulation Market, by Dosage Form
12.1.1. Oral Solid Dosage (tablets, capsules)
12.1.1.1. Market Revenue and Forecast
12.1.2. Parenterals (injectables, biologics formulations)
12.1.2.1. Market Revenue and Forecast
12.1.3. Inhalation & Pulmonary Drug Delivery
12.1.3.1. Market Revenue and Forecast
12.1.4. Transdermal / Topical Formulations
12.1.4.1. Market Revenue and Forecast
12.1.5. Nasal / Mucosal Delivery
12.1.5.1. Market Revenue and Forecast
12.1.6. Advanced Delivery Systems (liposomes, nanoparticles, LNPs)
12.1.6.1. Market Revenue and Forecast
13.1. North America
13.1.1. Market Revenue and Forecast, by Component
13.1.2. Market Revenue and Forecast, by Technology
13.1.3. Market Revenue and Forecast, by Application / Use Case
13.1.4. Market Revenue and Forecast, by Drug Type
13.1.5. Market Revenue and Forecast, by Dosage Form
13.1.6. U.S.
13.1.6.1. Market Revenue and Forecast, by Component
13.1.6.2. Market Revenue and Forecast, by Technology
13.1.6.3. Market Revenue and Forecast, by Application / Use Case
13.1.6.4. Market Revenue and Forecast, by Drug Type
13.1.6.5. Market Revenue and Forecast, by Dosage Form
13.1.7. Rest of North America
13.1.7.1. Market Revenue and Forecast, by Component
13.1.7.2. Market Revenue and Forecast, by Technology
13.1.7.3. Market Revenue and Forecast, by Application / Use Case
13.1.7.4. Market Revenue and Forecast, by Drug Type
13.1.7.5. Market Revenue and Forecast, by Dosage Form
13.2. Europe
13.2.1. Market Revenue and Forecast, by Component
13.2.2. Market Revenue and Forecast, by Technology
13.2.3. Market Revenue and Forecast, by Application / Use Case
13.2.4. Market Revenue and Forecast, by Drug Type
13.2.5. Market Revenue and Forecast, by Dosage Form
13.2.6. UK
13.2.6.1. Market Revenue and Forecast, by Component
13.2.6.2. Market Revenue and Forecast, by Technology
13.2.6.3. Market Revenue and Forecast, by Application / Use Case
13.2.7. Market Revenue and Forecast, by Drug Type
13.2.8. Market Revenue and Forecast, by Dosage Form
13.2.9. Germany
13.2.9.1. Market Revenue and Forecast, by Component
13.2.9.2. Market Revenue and Forecast, by Technology
13.2.9.3. Market Revenue and Forecast, by Application / Use Case
13.2.10. Market Revenue and Forecast, by Drug Type
13.2.11. Market Revenue and Forecast, by Dosage Form
13.2.12. France
13.2.12.1. Market Revenue and Forecast, by Component
13.2.12.2. Market Revenue and Forecast, by Technology
13.2.12.3. Market Revenue and Forecast, by Application / Use Case
13.2.12.4. Market Revenue and Forecast, by Drug Type
13.2.13. Market Revenue and Forecast, by Dosage Form
13.2.14. Rest of Europe
13.2.14.1. Market Revenue and Forecast, by Component
13.2.14.2. Market Revenue and Forecast, by Technology
13.2.14.3. Market Revenue and Forecast, by Application / Use Case
13.2.14.4. Market Revenue and Forecast, by Drug Type
13.2.15. Market Revenue and Forecast, by Dosage Form
13.3. APAC
13.3.1. Market Revenue and Forecast, by Component
13.3.2. Market Revenue and Forecast, by Technology
13.3.3. Market Revenue and Forecast, by Application / Use Case
13.3.4. Market Revenue and Forecast, by Drug Type
13.3.5. Market Revenue and Forecast, by Dosage Form
13.3.6. India
13.3.6.1. Market Revenue and Forecast, by Component
13.3.6.2. Market Revenue and Forecast, by Technology
13.3.6.3. Market Revenue and Forecast, by Application / Use Case
13.3.6.4. Market Revenue and Forecast, by Drug Type
13.3.7. Market Revenue and Forecast, by Dosage Form
13.3.8. China
13.3.8.1. Market Revenue and Forecast, by Component
13.3.8.2. Market Revenue and Forecast, by Technology
13.3.8.3. Market Revenue and Forecast, by Application / Use Case
13.3.8.4. Market Revenue and Forecast, by Drug Type
13.3.9. Market Revenue and Forecast, by Dosage Form
13.3.10. Japan
13.3.10.1. Market Revenue and Forecast, by Component
13.3.10.2. Market Revenue and Forecast, by Technology
13.3.10.3. Market Revenue and Forecast, by Application / Use Case
13.3.10.4. Market Revenue and Forecast, by Drug Type
13.3.10.5. Market Revenue and Forecast, by Dosage Form
13.3.11. Rest of APAC
13.3.11.1. Market Revenue and Forecast, by Component
13.3.11.2. Market Revenue and Forecast, by Technology
13.3.11.3. Market Revenue and Forecast, by Application / Use Case
13.3.11.4. Market Revenue and Forecast, by Drug Type
13.3.11.5. Market Revenue and Forecast, by Dosage Form
13.4. MEA
13.4.1. Market Revenue and Forecast, by Component
13.4.2. Market Revenue and Forecast, by Technology
13.4.3. Market Revenue and Forecast, by Application / Use Case
13.4.4. Market Revenue and Forecast, by Drug Type
13.4.5. Market Revenue and Forecast, by Dosage Form
13.4.6. GCC
13.4.6.1. Market Revenue and Forecast, by Component
13.4.6.2. Market Revenue and Forecast, by Technology
13.4.6.3. Market Revenue and Forecast, by Application / Use Case
13.4.6.4. Market Revenue and Forecast, by Drug Type
13.4.7. Market Revenue and Forecast, by Dosage Form
13.4.8. North Africa
13.4.8.1. Market Revenue and Forecast, by Component
13.4.8.2. Market Revenue and Forecast, by Technology
13.4.8.3. Market Revenue and Forecast, by Application / Use Case
13.4.8.4. Market Revenue and Forecast, by Drug Type
13.4.9. Market Revenue and Forecast, by Dosage Form
13.4.10. South Africa
13.4.10.1. Market Revenue and Forecast, by Component
13.4.10.2. Market Revenue and Forecast, by Technology
13.4.10.3. Market Revenue and Forecast, by Application / Use Case
13.4.10.4. Market Revenue and Forecast, by Drug Type
13.4.10.5. Market Revenue and Forecast, by Dosage Form
13.4.11. Rest of MEA
13.4.11.1. Market Revenue and Forecast, by Component
13.4.11.2. Market Revenue and Forecast, by Technology
13.4.11.3. Market Revenue and Forecast, by Application / Use Case
13.4.11.4. Market Revenue and Forecast, by Drug Type
13.4.11.5. Market Revenue and Forecast, by Dosage Form
13.5. Latin America
13.5.1. Market Revenue and Forecast, by Component
13.5.2. Market Revenue and Forecast, by Technology
13.5.3. Market Revenue and Forecast, by Application / Use Case
13.5.4. Market Revenue and Forecast, by Drug Type
13.5.5. Market Revenue and Forecast, by Dosage Form
13.5.6. Brazil
13.5.6.1. Market Revenue and Forecast, by Component
13.5.6.2. Market Revenue and Forecast, by Technology
13.5.6.3. Market Revenue and Forecast, by Application / Use Case
13.5.6.4. Market Revenue and Forecast, by Drug Type
13.5.7. Market Revenue and Forecast, by Dosage Form
13.5.8. Rest of LATAM
13.5.8.1. Market Revenue and Forecast, by Component
13.5.8.2. Market Revenue and Forecast, by Technology
13.5.8.3. Market Revenue and Forecast, by Application / Use Case
13.5.8.4. Market Revenue and Forecast, by Drug Type
13.5.8.5. Market Revenue and Forecast, by Dosage Form
14.1. Exscientia
14.1.1. Company Overview
14.1.2. Product Offerings
14.1.3. Financial Performance
14.1.4. Recent Initiatives
14.2. Atomwise
14.2.1. Company Overview
14.2.2. Product Offerings
14.2.3. Financial Performance
14.2.4. Recent Initiatives
14.3. Schrödinger
14.3.1. Company Overview
14.3.2. Product Offerings
14.3.3. Financial Performance
14.3.4. Recent Initiatives
14.4. BenevolentAI
14.4.1. Company Overview
14.4.2. Product Offerings
14.4.3. Financial Performance
14.4.4. Recent Initiatives
14.5. Cyclica (part of Recursion)
14.5.1. Company Overview
14.5.2. Product Offerings
14.5.3. Financial Performance
14.5.4. Recent Initiatives
14.6. DeepMatter
14.6.1. Company Overview
14.6.2. Product Offerings
14.6.3. Financial Performance
14.6.4. Recent Initiatives
14.7. IBM Watson Health
14.7.1. Company Overview
14.7.2. Product Offerings
14.7.3. Financial Performance
14.7.4. Recent Initiatives
14.8. Standigm
14.8.1. Company Overview
14.8.2. Product Offerings
14.8.3. Financial Performance
14.8.4. Recent Initiatives
14.9. Valo Health
14.9.1. Company Overview
14.9.2. Product Offerings
14.9.3. Financial Performance
14.9.4. Recent Initiatives
14.10. Abbott
14.10.1. Company Overview
14.10.2. Product Offerings
14.10.3. Financial Performance
14.10.4. Recent Initiatives
15.1. Primary Research
15.2. Secondary Research
15.3. Assumptions
16.1. About Us
16.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client